Drug intelligence / Profile preview

methylphenidate + cannabidiol

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

A combination of methylphenidate (MPH), a central nervous system stimulant used primarily for treating ADHD, and cannabidiol (CBD), a non-psychoactive cannabinoid. In vitro studies have shown that CBD can inhibit carboxylesterase 1 (CES1), the enzyme responsible for metabolizing methylphenidate, suggesting a potential pharmacokinetic interaction. Clinical studies have found this interaction to be weak and likely clinically insignificant at standard therapeutic doses.

Brand names: RitalinEpidiolex
Other names: MPH + CBDdl-methylphenidate + cannabidiol

Targets

CNR1 (Cannabinoid receptor 1)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)CES1 (Liver carboxylesterase 1)

Beyond the preview

Go deeper on methylphenidate + cannabidiol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on methylphenidate + cannabidiol.

Explore the full profile